Core Viewpoint - Beida Pharmaceutical Co., Ltd. announced that four of its innovative drugs have been included in the National Medical Insurance Directory for 2025, reflecting the recognition of the company's innovation capabilities and the clinical value of its drugs by the national medical insurance department [1][5]. Group 1: Drug Information - The four drugs included are: 1. **Erlotinib Hydrochloride Tablets** - the first domestically developed EGFR-TKI for lung cancer treatment with independent intellectual property rights [1]. 2. **Ensartinib Capsules** - a new generation ALK inhibitor co-developed with Xcovery [1]. 3. **Befotnib** - a third-generation EGFR-TKI and a national class 1 innovative drug with independent intellectual property rights [2]. 4. **Vorolanib Tablets** - a new multi-target tyrosine kinase inhibitor that can inhibit tumor angiogenesis and is used for treating pathological angiogenesis diseases [2]. Group 2: Impact on Business - Inclusion in the National Medical Insurance Directory is expected to enhance the accessibility of these products and positively impact sales [5]. - The directory will be effective from January 1, 2026, and the immediate impact on the company's operating performance cannot be accurately estimated at this time [5].

Core Viewpoint - The announcement by Beida Pharmaceutical regarding the inclusion of its products in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025 is a significant development for the company and its market positioning [1] Group 1 - Beida Pharmaceutical has announced that its products, including Alectinib Hydrochloride Tablets, Ensartinib Capsules, Bafetinib Mesylate Capsules, and Vorinostat Tablets, have been included in the National Drug List for 2025 [1]

Core Viewpoint - The announcement indicates that several products from the company have been included in the National Medical Insurance Drug List for 2025, which is expected to enhance accessibility and positively impact sales, although the exact effect on current performance cannot be accurately estimated [1] Group 1 - The products included are: - Hydrochloride Alectinib Tablets - Hydrochloride Ensartinib Capsules - Mesylate Bafetinib Capsules - Vorinostat Tablets These products will be effective from January 1, 2026, to December 31, 2027 [1] - Additionally, the product Bevacizumab Injection has been included in the National Medical Insurance Category B Drug List [1] Group 2 - Inclusion in the medical insurance list is expected to improve product accessibility [1] - The impact on sales is anticipated to be positive, although the company cannot currently provide an accurate estimate of the effect on its performance [1]

Policy Developments - The National Healthcare Security Administration exposed a healthcare fraud industry chain in Shanghai, leading to the prosecution of an individual for fraud, resulting in significant losses to the national healthcare fund [1] - The crackdown on healthcare fraud has become more systematic and normalized in recent years, highlighting the importance of protecting the healthcare fund [1] Drug and Device Approvals - Anglicon received a drug registration certificate for Ertugliflozin Metformin Extended-Release Tablets, aimed at improving blood sugar control in adults with type 2 diabetes [2] - Betta Pharmaceuticals announced that its application for the marketing authorization of Ensartinib Capsules for treating ALK-positive non-small cell lung cancer has been accepted by the European Medicines Agency [3] - Innovent Biologics received approval for its IL-23p19 monoclonal antibody for the treatment of moderate to severe plaque psoriasis in adults [4] - Warner Pharmaceuticals obtained a drug registration certificate for Formoterol Fumarate Inhalation Solution, intended for the maintenance treatment of COPD [5] - Shanghai Pharmaceuticals announced that its Tramadol Hydrochloride Injection passed the consistency evaluation for generic drugs, which may enhance its market competitiveness [6] Major Industry Events - Biontech received a milestone payment of $250 million from Bristol-Myers Squibb related to the Iza-bren project, with potential for additional payments based on future milestones [7] - Jining Pharmaceutical plans to invest 893 million yuan in a hospital expansion project to meet the growing health demands in the region [8] - Maiwei Biotech completed Phase IIa clinical trials for its innovative drug 9MW1911 in COPD patients, showing significant reductions in acute exacerbation rates [9] Shareholder Actions - Sanofi Biotech announced plans for shareholders to reduce their holdings by a total of 0.0240% of shares due to personal financial needs [10] Management Changes - Sinopharm Holdings announced management changes, including the resignation of several executives and the appointment of new leadership, which will take effect upon shareholder approval [11]

Group 1 - The core point of the article is that Xcovery Holdings, a subsidiary of Betta Pharmaceuticals, has submitted a marketing authorization application for ensartinib capsules to the European Medicines Agency (EMA) for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients [1] - The drug is a novel, potent, and highly selective ALK inhibitor that has already been approved for second-line and first-line indications in China [1] - The FDA is expected to approve the drug for market launch in the United States by December 2024, and the EMA has officially accepted the application for marketing authorization [1]

Core Viewpoint - Xcovery Holdings, a subsidiary of BeiGene, has received acceptance from the European Medicines Agency (EMA) for its marketing authorization application for ensartinib capsules, intended for the treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [2] Group 1 - The marketing authorization application for ensartinib has been officially accepted by the EMA [2] - The drug is specifically aimed at treating adult patients with ALK-positive locally advanced or metastatic NSCLC [2]

Core Viewpoint - Xcovery, a subsidiary of BeiGene, has received acceptance from the European Medicines Agency (EMA) for its marketing authorization application for ensartinib capsules, intended for the treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [1] Group 1 - Xcovery is a controlling subsidiary of BeiGene [1] - The application submitted by Xcovery is specifically for ensartinib capsules [1] - The target patient population for this treatment includes adults with ALK-positive locally advanced or metastatic NSCLC [1]

Core Viewpoint - The announcement indicates that Xcovery, a subsidiary of BeiGene, has received acceptance from the European Medicines Agency (EMA) for the marketing authorization application of ensartinib capsules for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients [1] Group 1 - Xcovery submitted a marketing authorization application for ensartinib to the EMA [1] - Ensartinib is a new generation ALK inhibitor that is highly selective and potent [1] - The drug was previously approved by the National Medical Products Administration (NMPA) in China for second-line treatment in November 2020 and for first-line treatment in March 2022 [1]

Core Viewpoint - Betta Pharmaceuticals has received acceptance from the National Medical Products Administration (NMPA) for its application of crizotinib capsules (brand name: Baimena®) for postoperative adjuvant therapy in ALK-positive non-small cell lung cancer (NSCLC) patients [2] Group 1 - The NMPA issued an acceptance notice for the application with reference numbers CXHS2500142 and CXHS2500143 [2] - The indication for the drug is specifically for patients with stage IB to IIIB ALK-positive NSCLC who have previously undergone surgical resection [2] - The decision for patients to receive adjuvant chemotherapy is at the discretion of their physician [2]

Core Viewpoint - The company has received acceptance from NMPA for the marketing authorization application of Ensartinib capsules for postoperative adjuvant therapy in ALK-positive non-small cell lung cancer (NSCLC) patients [1] Group 1: Product Development - Ensartinib is a new generation ALK inhibitor that is highly selective and potent [1] - The drug was previously approved by NMPA in November 2020 for the treatment of ALK-positive locally advanced or metastatic NSCLC patients who progressed after or are intolerant to Crizotinib [1] Group 2: Clinical Data - Mid-term results of postoperative adjuvant therapy with Ensartinib will be disclosed at the 2025 European Society for Medical Oncology (ESMO) annual meeting [1] - The 2-year disease-free survival (DFS) rate for patients receiving postoperative adjuvant therapy with Ensartinib is reported to be 86.4% [1] - The risk ratio for 2-year DFS is 0.20, indicating an 80% reduction in the risk of recurrence, significantly lowering the likelihood of disease relapse [1]